Literature DB >> 21640975

SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis.

Keith W McLarren1, Alexandra E Cole, Shelley B Weisser, Nicole S Voglmaier, Victoria S Conlin, Kevan Jacobson, Oana Popescu, Jean-Luc Boucher, Laura M Sly.   

Abstract

Intestinal fibrosis is a serious complication of Crohn's disease (CD) that can lead to stricture formation, which requires surgery. Mechanisms underlying intestinal fibrosis remain elusive because of a lack of suitable mouse models. Herein, we describe a spontaneous mouse model of intestinal inflammation with fibrosis and the profibrotic role of arginase I. The Src homology 2 domain-containing inositol polyphosphate 5'-phosphatase-deficient (SHIP(-/-)) mice developed spontaneous discontinuous intestinal inflammation restricted to the distal ileum starting at the age of 4 weeks. Mice developed several key features resembling CD, including inflammation and fibrosis. Inflammation was characterized by abundant infiltrating Gr-1-positive immune cells, granuloma-like immune cell aggregates that contained multinucleated giant cells, and a mixed type 2 and type 17 helper T-cell cytokine profile. Fibrosis was characterized by a thickened ileal muscle layer, collagen deposition, and increased fibroblasts at the sites of collagen deposition. SHIP(-/-) ilea had increased arginase activity and arginase I expression that was inversely proportional to nitrotyrosine staining. SHIP(-/-) mice were treated with the arginase inhibitor S-(2-boronoethyl)-l-cysteine, and changes in the disease phenotype were measured. Arginase inhibition did not affect the number of immune cell infiltrates in the SHIP(-/-) mouse ilea; rather, it reduced collagen deposition and muscle hyperplasia. These findings suggest that arginase activity is a potential target to limit intestinal fibrosis in patients with CD.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640975      PMCID: PMC3123870          DOI: 10.1016/j.ajpath.2011.03.018

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  SHIP represses Th2 skewing by inhibiting IL-4 production from basophils.

Authors:  Etsushi Kuroda; Frann Antignano; Victor W Ho; Michael R Hughes; Jens Ruschmann; Vivian Lam; Toshiaki Kawakami; William G Kerr; Kelly M McNagny; Laura M Sly; Gerald Krystal
Journal:  J Immunol       Date:  2010-12-03       Impact factor: 5.422

3.  The epidemiology of inflammatory bowel disease in Canada: a population-based study.

Authors:  Charles N Bernstein; Andre Wajda; Lawrence W Svenson; Adrian MacKenzie; Mieke Koehoorn; Maureen Jackson; Richard Fedorak; David Israel; James F Blanchard
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

4.  Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1.

Authors:  Y Motomura; W I Khan; R T El-Sharkawy; M Verma-Gandhu; E F Verdu; J Gauldie; S M Collins
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 5.  Structure and biological activity of the extracellular matrix.

Authors:  M Aumailley; B Gayraud
Journal:  J Mol Med (Berl)       Date:  1998-03       Impact factor: 4.599

6.  The granulomatous inflammatory response. A review.

Authors:  D O Adams
Journal:  Am J Pathol       Date:  1976-07       Impact factor: 4.307

7.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B.

Authors:  Ian C Lawrance; Feng Wu; André Z A Leite; Joseph Willis; Gail A West; Claudio Fiocchi; Shukti Chakravarti
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 8.  Medical therapy for Crohn's disease strictures.

Authors:  Gert Van Assche; Karel Geboes; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

9.  Derivation and characterization of murine alternatively activated (M2) macrophages.

Authors:  Victor W H Ho; Laura M Sly
Journal:  Methods Mol Biol       Date:  2009

10.  Common variants at five new loci associated with early-onset inflammatory bowel disease.

Authors:  Marcin Imielinski; Robert N Baldassano; Anne Griffiths; Richard K Russell; Vito Annese; Marla Dubinsky; Subra Kugathasan; Jonathan P Bradfield; Thomas D Walters; Patrick Sleiman; Cecilia E Kim; Aleixo Muise; Kai Wang; Joseph T Glessner; Shehzad Saeed; Haitao Zhang; Edward C Frackelton; Cuiping Hou; James H Flory; George Otieno; Rosetta M Chiavacci; Robert Grundmeier; Massimo Castro; Anna Latiano; Bruno Dallapiccola; Joanne Stempak; Debra J Abrams; Kent Taylor; Dermot McGovern; Gary Silber; Iwona Wrobel; Antonio Quiros; Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmuda; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephen R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; J P Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwillam; Mark Tremelling; Panos Delukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly; Melvin B Heyman; George D Ferry; Barbara Kirschner; Jessica Lee; Jonah Essers; Richard Grand; Michael Stephens; Arie Levine; David Piccoli; John Van Limbergen; Salvatore Cucchiara; Dimitri S Monos; Stephen L Guthery; Lee Denson; David C Wilson; Straun F A Grant; Mark Daly; Mark S Silverberg; Jack Satsangi; Hakon Hakonarson
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  14 in total

1.  Bidirectional crosstalk via IL-6, PGE2 and PGD2 between murine myofibroblasts and alternatively activated macrophages enhances anti-inflammatory phenotype in both cells.

Authors:  Maria R Fernando; Mark A Giembycz; Derek M McKay
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

2.  AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.

Authors:  Jennifer Cross; Grant R Stenton; Curtis Harwig; Csaba Szabo; Tiziana Genovese; Rosanna Di Paola; Emanuale Esposito; Salvatore Cuzzocrea; Lloyd F Mackenzie
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

3.  The Crohn's disease-associated polymorphism in ATG16L1 (rs2241880) reduces SHIP gene expression and activity in human subjects.

Authors:  E N Ngoh; H K Brugger; M Monajemi; S C Menzies; A F Hirschfeld; K L Del Bel; K Jacobson; P M Lavoie; S E Turvey; L M Sly
Journal:  Genes Immun       Date:  2015-07-30       Impact factor: 2.676

4.  SHIP-1 deficiency in the myeloid compartment is insufficient to induce myeloid expansion or chronic inflammation.

Authors:  M J Maxwell; N Srivastava; M-Y Park; E Tsantikos; R W Engelman; W G Kerr; M L Hibbs
Journal:  Genes Immun       Date:  2014-03-06       Impact factor: 2.676

5.  Inhibition of chlorine-induced airway fibrosis by budesonide.

Authors:  Sadiatu Musah; Jing Chen; Connie Schlueter; David M Humphrey; Kendall Stocke; Mona I Hoyle; Gary W Hoyle
Journal:  Toxicol Appl Pharmacol       Date:  2018-09-03       Impact factor: 4.219

6.  Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia.

Authors:  Dalia Haydar; Rene Gonzalez; Beth A Garvy; Sylvie Garneau-Tsodikova; Nishad Thamban Chandrika; Therese J Bocklage; David J Feola
Journal:  Immunobiology       Date:  2020-11-24       Impact factor: 3.144

7.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

8.  The inositol phosphatase SHIP-1 inhibits NOD2-induced NF-κB activation by disturbing the interaction of XIAP with RIP2.

Authors:  Claude Condé; Xavier Rambout; Marielle Lebrun; Aurore Lecat; Emmanuel Di Valentin; Franck Dequiedt; Jacques Piette; Geoffrey Gloire; Sylvie Legrand
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 9.  Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment.

Authors:  Lida Iliopoulou; George Kollias
Journal:  Mucosal Immunol       Date:  2021-07-27       Impact factor: 7.313

10.  Expression of arginase I and inducible nitric oxide synthase in the peripheral blood and lymph nodes of HIV‑positive patients.

Authors:  Naichun Zhang; Jianning Deng; Fengyao Wu; Xiangchan Lu; Lei Huang; Min Zhao
Journal:  Mol Med Rep       Date:  2015-11-23       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.